Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications
Medicinal Research Reviews · 2026
DOI: 10.1002/med.70008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Marius Müller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Astatine, Radiopharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by Danmarks Frie Forskningsfond (1032-00177B)..
Abstract (Originalsprache)
Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 ( 211 At) has experienced increased interest due to its favorable decay properties. As a result, various 211 At‐astatination strategies have been developed to address challenges associated with working with this “halogenic metalloid.” This review summarizes efforts to produce and scale 211 At, describes its physicochemical properties, discusses the advantages and disadvantages of using a radionuclide with a half‐life of 7.2 h and outlines procedures for astatinating radiopharmaceuticals. Moreover, a key focus of this review is to rationalize strategies aimed at minimizing in vivo deastatination. A brief overview of on‐going (pre)clinical development with 211 At‐labeled radiopharmaceuticals is provided. Astatinated radiopharmaceuticals will play a pivotal role in cancer management in the near future when challenges related to scalability and in vivo stability have been addressed and clinical studies have shown the benefit of 211 At compared to longer‐lived therapeutic radionuclides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark.
- Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark.
- DTU Health Technology, Technical University of Denmark (DTU), Lyngby, Denmark.
ORCID-Profile: Nadia Bom Pedersen, Andreas Ingemann Jensen, Umberto Maria Battisti
Förderung
- This study was supported by Danmarks Frie Forskningsfond (1032-00177B).
Zitieren
APA
Müller, M., Pedersen, N. B., Shalgunov, V., Jensen, A. I., Battisti, U. M., & Herth, M. M. (2026). Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications. Medicinal Research Reviews. https://doi.org/10.1002/med.70008
Vancouver
Müller M, Pedersen NB, Shalgunov V, Jensen AI, Battisti UM, Herth MM. Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications. Medicinal Research Reviews. 2026. doi:10.1002/med.70008
BibTeX
@article{Mller2026,
author = {Müller, Marius and Pedersen, Nadia Bom and Shalgunov, Vladimir and Jensen, Andreas Ingemann and Battisti, Umberto Maria and Herth, Matthias Manfred},
title = {Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70008}
}
EUVIMED